TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03085511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg breakfast (EB)
Description: Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
Study: NCT03829787

Intervention type: DEVICE
Intervention: Eye tracking
Description: Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
Study: NCT03085511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Diet
Description: Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Diet
Description: Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Breakfast (CB)
Description: Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
Study: NCT00378911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT01709942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix (long acting GnRH antagonist)
Description: 20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix 0.25mg
Description: 0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
Study: NCT00966290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant (warfarin, acenocoumarol, fluindione)
Description: Anticoagulant clinic based shared-care group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant (warfarin, acenocoumarol, fluindione)
Description: Usual care group
Study: NCT03225261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus extract
Description: Citrus extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT04151251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Empowerment
Description: Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Kit
Description: Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Kit
Description: Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
Study: NCT02466113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A 6 microRNA stratified tool
Description: Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
Study: NCT03972280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Description: Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
Study: NCT04347239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab (700mg)
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT02619292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Movement Program
Description: Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
Study: NCT03945396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic Medication
Description: A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (Exercise program, diet, motivational support)
Description: Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary intervention (Exercise program, diet, motivational support)
Description: Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic placebo
Description: A 30 ml bottle of 30% alcohol-distilled water.
Study: NCT01712607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Warm-Up training
Description: Preoperative Warm-Up training
Study: NCT00875225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD
Description: Control group will receive usual care DVD from health professionals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention DVD
Description: Intervention group will receive intervention DVD with patient stories and information from health care professionals
Study: NCT04043091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention (stenting)
Description: percutaneous stent implantation in coronary artery
Study: NCT02518399

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water immersion
Description: Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
Study: NCT03168230

Intervention type: PROCEDURE
Intervention: Portal vein embolization (PVE)
Description: Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx
Study: NCT01716975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arms 1, 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: Arms 1, 2
Study: NCT00453544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Consent Procedure
Description: This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Consent Procedure
Description: This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Consent Procedure
Description: This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Consent Procedure
Description: This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
Study: NCT01359657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CXCR4 (BMS-936564)
Description: Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CXCR4 (BMS-936564)
Description: Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
Study: NCT03434054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: blood pressure medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active sham intervention
Study: NCT01331954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation device
Description: One or two HIFU procedures
Study: NCT00534274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Study: NCT02223273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted Strategy
Description: 1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices
Study: NCT00362115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT01558752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip replacement with titanium shell and CORAIL stem
Description: Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement with Modular Titanium Femoral Stem
Description: Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
Study: NCT03985514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).
Description: Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.

Intervention type: OTHER
Group type: OTHER
Intervention: Active observation
Description: In-hospital observation without antibiotics
Study: NCT00450333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo (Epoetin delta)
Description: subcutaneous, BIW for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo
Description: subcutaneous, QW for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo
Description: subcutaneous, QW for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo
Description: subcutaneous, Q2W for 24 weeks
Study: NCT01927666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100mg glucoraphanin
Description: The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
Study: NCT01601782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).
Description: The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
Study: NCT01622972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethyleneglycol
Description: Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethyleneglycol
Description: Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethyleneglycol
Description: Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
Study: NCT04265781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Three different doses over the course of study
Study: NCT01716975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 3
Study: NCT04265781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Three different doses over the course of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo to BAY1817080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo to BAY1817080
Study: NCT04489329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ingestible Capsule
Description: Participants will swallow capsule and undergo X-rays to establish transit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
Study: NCT02028741

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transverse vertebral pressures
Description: Graded transverse mobilization directed to the thoracic spine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transverse vertebral pressures
Description: Graded transverse mobilization directed to the thoracic spine
Study: NCT02853578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busonid (budesonide 200mcg and 400mcg)
Description: cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.
Study: NCT01352780

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Motivational interviewing
Description: Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening.
Study: NCT01772212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Description: Test product